New pancreatic cancer registry aims to unlock disease secrets

NCT ID NCT01102556

Recruiting now Knowledge-focused Sponsor: Columbia University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

The PREDICT study is creating a registry and biospecimen bank for people with pancreatic disease or at high risk for pancreatic cancer. Researchers will collect blood, tissue, urine, and other samples from 1,000 participants to study the causes and biology of the disease. This is not a treatment trial, but the information gathered may help improve future diagnosis, prevention, and care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this registry could help researchers discover new ways to diagnose, prevent, and treat pancreatic cancer in the future.
What could go wrong: This is an observational study that collects data and samples, not a treatment trial. It will not directly benefit participants and may not lead to immediate breakthroughs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intraepithelial neoplasia malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic intraductal papillary-mucinous neoplasm pancreatic mucinous-cystic neoplasm pancreatic neoplasm pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.